US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

GSK plc ADRhedged

70.59

+0.73311.05%

Volume:112

Turnover:7.90K

Market Cap:705.97K

PE:- -

High:70.59

Open:70.59

Low:70.59

Close:69.86

52wk High:85.03

52wk Low:55.03

Shares:10.00K

Float Shares:10.00K

Volume Ratio:0.59

T/O Rate:1.12%

Dividend:2.07

Dividend Rate:2.94%

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

European Pharma Stocks' Underperformance Shouldn't Last

GSK Oncology Portfolio Seems Underrated

Sector Update: Healthcare

MT Newswires Live

GlaxoSmithKline (GSK) Gets a Buy from Jefferies

GSK Shares Slide After Drugmaker Drops Chronic Cough Treatment

GlaxoSmithKline (GSK) Gets a Sell from J.P. Morgan

GSK Will Likely Need to Book Write-down on Cough Drug Failure

GSK Stops Camlipixant Program in Refractory Chronic Cough After Phase 3 Data

MT Newswires Live

GSK Halts Camlipixant Development in Chronic Cough After Mixed Phase III Results

GSK Advances New Infant Pneumococcal Vaccine Into Early-Stage Testing

GSK executives boost holdings via dividend-funded ADS purchases

GSK’s New Phase 3 Ovarian Cancer Trial Puts Mo-Rez in the First-Line Spotlight

Is AnaptysBio (ANAB) Undervalued Following Its Jemperli Royalty Appeal And GSK Trial?

Simply Wall St.

GSK Completes $10.6 Billion Acquisition of Nuvalent

MT Newswires Live

iX Biopharma Warrants See Strong Insider Take-Up, Funding U.S. Expansion

GSK Executives Acquire Shares Under Routine Reward Plan

UBS Remains a Hold on GlaxoSmithKline (GSK)

GSK’s Jemperli Trial Points to Chemo‑Free Future for Subset of Rectal Cancer Patients

Insilico Medicine Surges Over 7% in Morning Trading on New AI Drug Discovery Partnership with CMS

Guggenheim Remains a Hold on GlaxoSmithKline (GSK)

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://sg.tigeractivity.com/stock/GSKH/news?page=4"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"GSKH","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"GSKH\",,,,,undefined,":{"symbol":"GSKH","market":"US","secType":"STK","nameCN":"GSK plc ADRhedged","latestPrice":70.59,"timestamp":1788278530270,"preClose":69.8569,"halted":0,"volume":112,"delay":0,"changeRate":0.010494310511918042,"floatShares":10001,"shares":10001,"eps":0,"marketStatus":"Trading","change":0.7331,"latestTime":"09-01 12:17:07 EDT","open":70.59,"high":70.59,"low":70.59,"amount":7898.42256,"amplitude":0,"askPrice":70.44,"askSize":100,"bidPrice":70.33,"bidSize":100,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1788292800000},"marketStatusCode":2,"adr":0,"exchange":"ARCA","adjPreClose":69.8569,"nav":70.443211,"aum":704502.553211,"dividendRate":0.029392,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":70.28,"preClose":69.8569,"latestTime":"16:10 EDT","volume":6,"amount":419.1414,"timestamp":1788207004353,"change":0.4231,"changeRate":0.006057,"amplitude":0},"volumeRatio":0.593065,"impliedVol":0.1633,"impliedVolPercentile":0.3113},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"GSKH\",,,,,undefined,":{"symbol":"GSKH","floatShares":10001,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.593065,"shares":10001,"dividePrice":2.0748,"high":70.59,"amplitude":0,"preClose":69.8569,"low":70.59,"week52Low":55.03,"pbRate":"--","week52High":85.03,"institutionHeld":0,"latestPrice":70.59,"eps":0,"divideRate":0.029392,"volume":112,"delay":0,"ttmEps":0,"open":70.59,"prevYearClose":68.2031,"prevWeekClose":70.5267,"prevMonthClose":69.8569,"prevQuarterClose":73.8574,"fiveDayClose":71.8401,"twentyDayClose":71.5353,"sixtyDayClose":73.2013},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/GSKH\",params:#limit:5,,,undefined,":[{"date":"2026-06-16","symbol":"GSKH","amount":0.92785,"announcedDate":"2026-06-15","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-06-16","defaultRemindTime":1781616600000,"name":"GSK plc ADRhedged","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-06-23","payableDate":"2026-06-16","currency":"USD","dateTimestamp":1781582400000,"payDate":"2026-06-23"},{"date":"2026-03-16","symbol":"GSKH","amount":0.36332,"announcedDate":"2026-03-13","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-03-16","defaultRemindTime":1773667800000,"name":"GSK plc ADRhedged","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-03-23","payableDate":"2026-03-16","currency":"USD","dateTimestamp":1773633600000,"payDate":"2026-03-23"},{"date":"2025-12-16","symbol":"GSKH","amount":0.78682,"announcedDate":"2025-12-15","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-16","defaultRemindTime":1765895400000,"name":"GSK plc ADRhedged","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-24","payableDate":"2025-12-16","currency":"USD","dateTimestamp":1765861200000,"payDate":"2025-12-24"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"GSKH\",market:\"US\",,,undefined,":[{"executeDate":"2025-12-16","recordDate":"2025-12-16","paymentDate":"2025-12-24","value":0.78682,"currency":"USD"},{"executeDate":"2026-03-16","recordDate":"2026-03-16","paymentDate":"2026-03-23","value":0.36332,"currency":"USD"},{"executeDate":"2026-06-16","recordDate":"2026-06-16","paymentDate":"2026-06-23","value":0.92785,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"GSKH\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"GSKH\",pageSize:20,pageCount:4,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2652286740","title":"European Pharma Stocks' Underperformance Shouldn't Last","url":"https://stock-news.laohu8.com/highlight/detail?id=2652286740","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2652286740?lang=en_us&edition=fundamental","pubTime":"2026-07-17 22:13","pubTimestamp":1784297580,"startTime":"0","endTime":"0","summary":"1413 GMT - European pharma stocks are lagging behind the broader market, but the sector should benefit as investors start to look for trades beyond big tech, Intron Health's Naresh Chouhan and Dominic Rose say in a research note. This year's underperformance came after pricing deals with the Trump administration at the end of last year boosted the sector, Intron says. \"We do not believe investors have fallen out of love with pharma, it is just that many believe the sector is up with events for now,\" the analysts say. Upcoming strategy updates from companies like GSK, Novo Nordisk and Roche, and potential gains from AI should help pharma stocks, they add. Intron says it favors UCB, AstraZeneca, Roche and Novartis in the near term. The Stoxx Europe 600 Health Care index rises 0.3%.  Dow Jones NewswiresJuly 17, 2026 10:13 ET Copyright  2026 Dow Jones & Company, Inc.","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["THNR","LU1267930573.SGD","GSKH","LU2089984988.USD","LU2237443895.HKD","BK4532","IE0009355771.USD","BK4568","NVOH","GSK.UK","IE00BFTCPJ56.SGD","LU0208291251.USD","LU0289739699.SGD","IE00BJJMRZ35.SGD","BK4588","NVO","LU2468319806.SGD","LU0889565916.HKD","LU2462157665.USD","IE00BJT1NW94.SGD","IE00B4R5TH58.HKD","IE00BKVL7J92.USD","BK4007","IE00BZ1G4Q59.USD","BK4599","LU0432979614.USD","HRTS","LU1093756168.USD","PPH","LU2237443978.SGD","OZEM","LU0320765489.SGD","LU2237443622.USD","NVS","EPV","LU0070302665.USD","LU0128525929.USD","LU1093756325.SGD","LU0154236417.USD","LU0109394709.USD","IE00B3T34201.USD","LU0029864427.USD","LU2237443465.HKD","LU2417539215.USD","BK4578","IE00B2B36J28.USD","LU0708994859.HKD","LU2456880835.USD","NVOX","LU0058720904.USD","CANC","LU0320765992.SGD","LU0310800379.SGD","MEDX","03165","BK4585","LU2237443382.USD","AZN","LU1829250122.USD","LU0211331839.USD","LU2236285917.USD","LU2237443549.SGD","AZNH","RHHBY","IE0002141913.USD","GSK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652666286","title":"GSK Oncology Portfolio Seems Underrated","url":"https://stock-news.laohu8.com/highlight/detail?id=2652666286","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2652666286?lang=en_us&edition=fundamental","pubTime":"2026-07-17 21:51","pubTimestamp":1784296260,"startTime":"0","endTime":"0","summary":"1351 GMT - GSK's oncology business has stronger assets than it is credited for and they could make a difference next decade, analysts at Jefferies say in a research note. The U.K. drugmaker has made a number of deals that add revenue potential without putting too much pressure on profitability and it still has room for more over the next few years, according to Jefferies. \"The acquisitions of IDRx as well as Nuvalent have added assets to the oncology portfolio that have one thing in common--long duration of therapy plus an ability to move up the treatment cascade,\" the analysts say. \"They are highly profitable assets that should start to contribute to the top-line as the HIV business starts to slow down.\" Shares fall 1.7%.  Dow Jones NewswiresJuly 17, 2026 09:51 ET Copyright  2026 Dow Jones & Company, Inc.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4532","BK4588","GSKH","GSK","LU1829250122.USD","BK4007","GSK.UK","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652858612","title":"Sector Update: Healthcare","url":"https://stock-news.laohu8.com/highlight/detail?id=2652858612","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2652858612?lang=en_us&edition=fundamental","pubTime":"2026-07-17 20:59","pubTimestamp":1784293167,"startTime":"0","endTime":"0","summary":"Healthcare stocks were mixed premarket Friday, with the State Street Health Care Select Sector SPDR ETF  up 0.3% and the iShares Biotechnology ETF  0.6% lower.GSK  shares were down more than 2% after the company said it will discontinue development of camlipixant for refractory chronic cough after the drug produced mixed results in the phase 3 CALM-1 and CALM-2 trials.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4532","BK4137","BK4588","LABU","LU1829250122.USD","XLV","GSK.UK","GSKH","IBB","LU0029874061.USD","BK4007","LU0128526141.USD","GSK","BK4581","HCSG","BK4585","XBI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652855285","title":"GlaxoSmithKline (GSK) Gets a Buy from Jefferies","url":"https://stock-news.laohu8.com/highlight/detail?id=2652855285","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2652855285?lang=en_us&edition=fundamental","pubTime":"2026-07-17 20:55","pubTimestamp":1784292936,"startTime":"0","endTime":"0","summary":"Jefferies analyst Michael Leuchten maintained a Buy rating on GlaxoSmithKline today and set a price target of £25.00. According to TipRanks, Leucht...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/glaxosmithkline-gsk-gets-a-buy-from-jefferies-blurbs-news-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/glaxosmithkline-gsk-gets-a-buy-from-jefferies-blurbs-news-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4532","BK4588","GSKH","BK4585","LU1829250122.USD","BK4007","GSK","GSK.UK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652834082","title":"GSK Shares Slide After Drugmaker Drops Chronic Cough Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2652834082","media":"Dow Jones","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2652834082?lang=en_us&edition=fundamental","pubTime":"2026-07-17 20:52","pubTimestamp":1784292720,"startTime":"0","endTime":"0","summary":"GSK shares fell after the U.K. drugmaker said it would stop working on an experimental treatment for chronic cough that showed limited efficacy in late-stage clinical studies.Shares in GSK were down 3","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"GSK Shares Slide After Drugmaker Drops Chronic Cough Treatment","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4585","GSK.UK","BK4588","GSK","LU1829250122.USD","GSKH","BK4532"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652285851","title":"GlaxoSmithKline (GSK) Gets a Sell from J.P. Morgan","url":"https://stock-news.laohu8.com/highlight/detail?id=2652285851","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2652285851?lang=en_us&edition=fundamental","pubTime":"2026-07-17 20:45","pubTimestamp":1784292326,"startTime":"0","endTime":"0","summary":"In a report released today, Zain Ebrahim from J.P. Morgan maintained a Sell rating on GlaxoSmithKline, with a price target of £17.00. According to ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/glaxosmithkline-gsk-gets-a-sell-from-j-p-morgan-blurbs-news-3?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/glaxosmithkline-gsk-gets-a-sell-from-j-p-morgan-blurbs-news-3?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU1732800096.USD","LU1548497426.USD","LU2487616109.SGD","LU1720051108.HKD","LU2264538146.SGD","LU2089283258.USD","BK4516","LU1988902786.USD","BK4532","LU1668664300.SGD","LU2133065610.SGD","IE00BKVL7J92.USD","LU0158827948.USD","LU0234570918.USD","LU2357305700.SGD","KBWB","LU1791710400.SGD","LU0158827781.USD","LU1244550494.USD","BK4127","BK4585","BK4534","LU2028103732.USD","LU0314104364.USD","GSKH","GSK.UK","LU0320765646.SGD","IAI","LU1074936037.SGD","BK4504","LU0795875169.SGD","LU1989772923.USD","LU0528227936.USD","LU2089284900.SGD","BK4588","GSK","LU0557290698.USD","LU0106831901.USD","LU1363072403.SGD","BK4007","LU0882574139.USD","LU1064131342.USD","LU0971096721.USD","LU1244550221.USD","LU0795875086.SGD","LU1829250122.USD","LU2023251221.USD","LU1162221912.USD","IE00BZ1G4Q59.USD","LU1791710582.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652288658","title":"GSK Will Likely Need to Book Write-down on Cough Drug Failure","url":"https://stock-news.laohu8.com/highlight/detail?id=2652288658","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2652288658?lang=en_us&edition=fundamental","pubTime":"2026-07-17 19:57","pubTimestamp":1784289420,"startTime":"0","endTime":"0","summary":"1156 GMT - GSK will likely need to take a write-down on an experimental drug for chronic cough after it stopped clinical development, J.P. Morgan analysts say in a research note. The U.K. drugmaker said it decided to terminate development of the drug for chronic cough after it delivered mixed results in a late-stage study and missed primary and secondary objectives in another trial. JPM estimated peak sales for the drug at 1.4 billion pounds, with 2031 sales forecast at 300 million pounds. GSK's recent acquisition of Nuvalent is likely to offset some of the hit from the loss of camlipixant, but shares are still expected to be under pressure, the analysts say. Shares fall 3.7%.  Dow Jones NewswiresJuly 17, 2026 07:57 ET Copyright  2026 Dow Jones & Company, Inc.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GSK.UK","BK4588","BK4532","BK4585","BK4007","LU1829250122.USD","GSKH","GSK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652402537","title":"GSK Stops Camlipixant Program in Refractory Chronic Cough After Phase 3 Data","url":"https://stock-news.laohu8.com/highlight/detail?id=2652402537","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2652402537?lang=en_us&edition=fundamental","pubTime":"2026-07-17 18:22","pubTimestamp":1784283728,"startTime":"0","endTime":"0","summary":"GSK  will discontinue development of camlipixant for refractory chronic cough after the drug produced mixed results in the phase 3 CALM-1 and CALM-2 trials, the company said Friday.In the phase 3 program, camlipixant 50 mg twice daily significantly reduced 24-hour cough frequency versus placebo in CALM-1 but failed to reach statistical significance in CALM-2, while the 25 mg dose failed to meet the primary endpoint in both trials.GSK said limited efficacy prompted its decision to discontinue camlipixant's development in refractory chronic cough, while the phase 2b BALANCE trial in irritable bowel syndrome will continue.GSK shares were down over 3% in premarket activity Friday.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["GSK","BK4532","GSK.UK","GSKH","BK4585","BK4007","LU1829250122.USD","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652406846","title":"GSK Halts Camlipixant Development in Chronic Cough After Mixed Phase III Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2652406846","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2652406846?lang=en_us&edition=fundamental","pubTime":"2026-07-17 16:32","pubTimestamp":1784277143,"startTime":"0","endTime":"0","summary":"The latest update is out from GlaxoSmithKline ( ($GB:GSK) ). GSK has reported mixed phase III results for its P2X3 receptor antagonist camlipixant ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/gsk-halts-camlipixant-development-in-chronic-cough-after-mixed-phase-iii-results?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/gsk-halts-camlipixant-development-in-chronic-cough-after-mixed-phase-iii-results?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4134","BK4007","BK4588","GSK","III","GSK.UK","BK4585","BK4532","GSKH","LU1829250122.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652042578","title":"GSK Advances New Infant Pneumococcal Vaccine Into Early-Stage Testing","url":"https://stock-news.laohu8.com/highlight/detail?id=2652042578","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2652042578?lang=en_us&edition=fundamental","pubTime":"2026-07-17 00:31","pubTimestamp":1784219518,"startTime":"0","endTime":"0","summary":"GlaxoSmithKline ($GSK) announced an update on their ongoing clinical study. GlaxoSmithKline is launching a Phase 1 trial to test an infant pneumoco...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/gsk-advances-new-infant-pneumococcal-vaccine-into-early-stage-testing?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/gsk-advances-new-infant-pneumococcal-vaccine-into-early-stage-testing?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4532","BK4588","GSKH","GSK","LU1829250122.USD","BK4007","GSK.UK","BK4585","BBC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651428983","title":"GSK executives boost holdings via dividend-funded ADS purchases","url":"https://stock-news.laohu8.com/highlight/detail?id=2651428983","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651428983?lang=en_us&edition=fundamental","pubTime":"2026-07-16 22:32","pubTimestamp":1784212352,"startTime":"0","endTime":"0","summary":"The latest update is out from GlaxoSmithKline ( ($GB:GSK) ). GSK has disclosed a series of transactions in which several senior executives and non-...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/gsk-executives-boost-holdings-via-dividend-funded-ads-purchases?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/gsk-executives-boost-holdings-via-dividend-funded-ads-purchases?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","LU1829250122.USD","VIG","GSKH","GSK","BK4588","BK4007","BK4532","GSK.UK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651467645","title":"GSK’s New Phase 3 Ovarian Cancer Trial Puts Mo-Rez in the First-Line Spotlight","url":"https://stock-news.laohu8.com/highlight/detail?id=2651467645","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651467645?lang=en_us&edition=fundamental","pubTime":"2026-07-16 00:31","pubTimestamp":1784133105,"startTime":"0","endTime":"0","summary":"GlaxoSmithKline ($GSK) announced an update on their ongoing clinical study. GlaxoSmithKline (GSK) is launching a phase 3 trial called BEHOLD-Ovaria...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/gsks-new-phase-3-ovarian-cancer-trial-puts-mo-rez-in-the-first-line-spotlight?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/gsks-new-phase-3-ovarian-cancer-trial-puts-mo-rez-in-the-first-line-spotlight?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU1829250122.USD","BK4532","BK4585","GSK","BK4007","GSK.UK","GSKH","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651846405","title":"Is AnaptysBio (ANAB) Undervalued Following Its Jemperli Royalty Appeal And GSK Trial?","url":"https://stock-news.laohu8.com/highlight/detail?id=2651846405","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651846405?lang=en_us&edition=fundamental","pubTime":"2026-07-15 22:36","pubTimestamp":1784126191,"startTime":"0","endTime":"0","summary":"Laughing Water Capital’s recent decision to add AnaptysBio (ANAB) has drawn attention because it hinges on two factors: royalty income from the cancer drug Jemperli and an imminent commercial trial with partner GSK.\nSee our latest analysis for AnaptysBio.\nDespite the recent legal spotlight, AnaptysBio’s share price has been volatile, with a 1-day share price return down 10.46% and a 7-day share price return down 7.15%. However, a year-to-date share price return of 39.07% sits alongside a very...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-anab/anaptysbio/news/is-anaptysbio-anab-undervalued-following-its-jemperli-royalt","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-anab/anaptysbio/news/is-anaptysbio-anab-undervalued-following-its-jemperli-royalt","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU1829250122.USD","ANAB","GSK.UK","BK4588","BK4007","BK4585","BK4139","FFTY","GSK","GSKH","BK4532"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651690154","title":"GSK Completes $10.6 Billion Acquisition of Nuvalent","url":"https://stock-news.laohu8.com/highlight/detail?id=2651690154","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651690154?lang=en_us&edition=fundamental","pubTime":"2026-07-15 22:16","pubTimestamp":1784124997,"startTime":"0","endTime":"0","summary":"GSK  said Wednesday it has completed the acquisition of Nuvalent , a Boston-based clinical-stage biopharmaceutical company, in a transaction with an aggregate equity value of about $10.6 billion.The transaction, which represents a net investment of about $9.4 billion after accounting for acquired cash, was finalized through a tender offer for all outstanding Nuvalent shares.The deal adds three lung cancer assets to GSK's oncology portfolio, according to a statement.Price: 51.55, Change: +0.30, Percent Change: +0.58","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4539","BK4139","BK4585","GSKH","BK4588","GSK","LU1829250122.USD","GSK.UK","NUVL","BK4007","BK4532"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651468729","title":"iX Biopharma Warrants See Strong Insider Take-Up, Funding U.S. Expansion","url":"https://stock-news.laohu8.com/highlight/detail?id=2651468729","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651468729?lang=en_us&edition=fundamental","pubTime":"2026-07-15 20:08","pubTimestamp":1784117284,"startTime":"0","endTime":"0","summary":"The latest update is out from iX Biopharma Ltd. ( ($SG:42C) ). Singapore-based iX Biopharma Ltd. operates in the biopharmaceutical industry, focusi...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/ix-biopharma-warrants-see-strong-insider-take-up-funding-u-s-expansion?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/ix-biopharma-warrants-see-strong-insider-take-up-funding-u-s-expansion?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MEDI","BK4209","SG","SURI","PPH","RSPH","GSKH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651110571","title":"GSK Executives Acquire Shares Under Routine Reward Plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2651110571","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651110571?lang=en_us&edition=fundamental","pubTime":"2026-07-13 22:32","pubTimestamp":1783953145,"startTime":"0","endTime":"0","summary":"GlaxoSmithKline ( ($GB:GSK) ) has provided an update. GSK has disclosed multiple small share acquisitions by senior executives under the company’s ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/gsk-executives-acquire-shares-under-routine-reward-plan?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/gsk-executives-acquire-shares-under-routine-reward-plan?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4532","BK4588","GSKH","GSK","LU1829250122.USD","BK4007","GSK.UK","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651511137","title":"UBS Remains a Hold on GlaxoSmithKline (GSK)","url":"https://stock-news.laohu8.com/highlight/detail?id=2651511137","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651511137?lang=en_us&edition=fundamental","pubTime":"2026-07-13 20:16","pubTimestamp":1783944989,"startTime":"0","endTime":"0","summary":"UBS analyst Matthew Weston maintained a Hold rating on GlaxoSmithKline today and set a price target of £19.40. According to TipRanks, Weston is a 4...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/ubs-remains-a-hold-on-glaxosmithkline-gsk-blurbs-news-3?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/ubs-remains-a-hold-on-glaxosmithkline-gsk-blurbs-news-3?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","GSK.UK","BK4588","BK4007","BK4532","GSK","LU1829250122.USD","GSKH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651954591","title":"GSK’s Jemperli Trial Points to Chemo‑Free Future for Subset of Rectal Cancer Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2651954591","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651954591?lang=en_us&edition=fundamental","pubTime":"2026-07-13 14:09","pubTimestamp":1783922982,"startTime":"0","endTime":"0","summary":"The latest update is out from GlaxoSmithKline ( ($GB:GSK) ). GSK has reported positive interim phase II AZUR-1 data for its PD‑1 inhibitor Jemperli...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/gsks-jemperli-trial-points-to-chemofree-future-for-subset-of-rectal-cancer-patients?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/gsks-jemperli-trial-points-to-chemofree-future-for-subset-of-rectal-cancer-patients?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","BK4532","BK4122","GSKH","GSK.UK","GSK","PCOM","LU1829250122.USD","BK4588","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1156997423","title":"Insilico Medicine Surges Over 7% in Morning Trading on New AI Drug Discovery Partnership with CMS","url":"https://stock-news.laohu8.com/highlight/detail?id=1156997423","media":"Deep News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1156997423?lang=en_us&edition=fundamental","pubTime":"2026-07-13 10:10","pubTimestamp":1783908642,"startTime":"0","endTime":"0","summary":"Insilico Medicine (03696) shares rose more than 7% in early trading. At the time of writing, the stock is up 6.21% to HK$45.48, with a turnover of HK$332 million. On July 13th, according to a post on...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARTY","LU2488822045.USD","BK1593","VTHR","BK4585","PBE","BK1191","SG9999015986.USD","SG9999015952.SGD","GDOC","SG9999015945.SGD","QTOC","IE00BVYPNP33.GBP","GSKH","00867","SG9999015978.USD","BK4588","SBIO","IE00BGHQDM52.EUR","IE00BMCWC346.EUR","IBB","BBP","IE00BVYPNQ40.USD","SG9999004220.SGD","IE00BYV24P56.USD","WRND","AIPO","LFSC","AGIX","CHAT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650139214","title":"Guggenheim Remains a Hold on GlaxoSmithKline (GSK)","url":"https://stock-news.laohu8.com/highlight/detail?id=2650139214","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650139214?lang=en_us&edition=fundamental","pubTime":"2026-07-10 23:45","pubTimestamp":1783698318,"startTime":"0","endTime":"0","summary":"Guggenheim analyst maintained a Hold rating on GlaxoSmithKline yesterday. The company’s shares closed today at p1,959.50. In addition to Guggenheim...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/guggenheim-remains-a-hold-on-glaxosmithkline-gsk-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/guggenheim-remains-a-hold-on-glaxosmithkline-gsk-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4532","GSK.UK","GSK","LU1829250122.USD","BK4588","BK4585","GSKH","BK4007"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":4,"totalSize":200,"code":"91000000","status":"200"}]}}